Prothena Corporation plc (NASDAQ:PRTA): $0.54 million was the positive money flow into the stock on Wednesday and the up/down ratio of ticks was also in favor of the bulls at 1.37. The value of trades done on upticks was $2.01 million, whereas, trades done on downticks were valued at $1.47 million. Money flows are calculated as the dollar value of composite uptick trades minus the dollar value of downtick trades. large traders, also sometimes called as the smart money, block traded $0.01 million worth stocks on upticks, which is a bullish indication. The money flow in block trades was $0.01 million. Prothena Corporation plc (NASDAQ:PRTA) fell $0.17 traded at $36.03, a change of -0.46% over the previous day. The stock is 1.54% for the week.
In an insider trading activity,The director of Prothena Corp Plc, Selkoe Dennis J. sold 5,000 shares at $45 on May 23, 2016. The Insider selling transaction had a total value worth of $225,000. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. Currently the company Insiders own 3.7% of Prothena Corporation plc shares according to the proxy statements.
The company shares have dropped -28.72% from its 1 Year high price. On Nov 30, 2015, the shares registered one year high at $76.42 and the one year low was seen on Feb 9, 2016. The 50-Day Moving Average price is $43.43 and the 200 Day Moving Average price is recorded at $44.18. Prothena Corporation plc (NASDAQ:PRTA): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $36.71 and $35.22 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $37.11. The buying momentum continued till the end and the stock did not give up its gains. It closed at $36.75, notching a gain of 1.55% for the day. The total traded volume was 477,057 . The stock had closed at $36.19 on the previous day.
Prothena Corporation Public Limited Company is an Ireland-based, late-stage clinical biotechnology company. The Company is focused on the discovery, development and commercialization of protein immunotherapy programs for the treatment of diseases that involve amyloid or cell adhesion. The Companys research and development pipeline includes three therapeutic antibody programs, such as NEOD001 for the treatment of AL amyloidosis; PRX002 in collaboration with Roche, for the treatment of Parkinsons disease and other related synucleinopathies, and PRX003 for the treatment of psoriasis and other inflammatory diseases. The Companys pipeline also includes several late discovery stage programs for which it is testing antibodies in preclinical models of diseases related to amyloid or cell adhesion.